M&A / Deals Jeito Capital secures over $1.2bn for new biopharma investments Pharmaceutical Business ReviewThe milestone increases Jeito's assets under management to 1.6bn, following the 534m closure of Jeito I in 2021.M&A / DealsRead full story pharminent April 9, 2026 (Last updated: April 9, 2026) Pharmaceutical Business Review The milestone increases Jeito’s assets under management to 1.6bn, following the 534m closure of Jeito I in 2021. M&A / DealsRead full story Post navigation Previous: FDA seeks permanent future for rare pediatric priority review vouchersNext: EverSea Medicines to acquire Hasten Biopharmaceuticals Related Stories M&A / Deals Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B pharminent May 13, 2026 M&A / Deals BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal pharminent May 12, 2026 M&A / Deals Cellular Intelligence scoops up Novo’s Parkinson’s therapy pharminent May 12, 2026
